Hospital
Tri-State Memorial Hospital
Tri-State Memorial Hospital was paid $14.46M by Medicaid between Jan 2018 and Dec 2024, across 207 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoTRI-STATE MEMORIAL HOSPITAL
CLARKSTON, WA 99403
CLARKSTON, WA 99403
33aNPI1760485221assigned 05/27/2005
33bProvider typeCritical Access Hospital
28Total paid$14.46M
24GClaims362,680
24DCodes billed207
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#9 of 30
Median peer was paid$9.10M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 59,606 | $2.05M | |
| 2019 | 57,744 | $2.08M | |
| 2020 | 46,626 | $1.99M | |
| 2021 | 52,080 | $1.92M | |
| 2022 | 55,780 | $2.20M | |
| 2023 | 52,149 | $2.27M | |
| 2024incomplete | 38,695 | $1.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 9,389 | 7,386 | $2.78M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 11,004 | 9,409 | $2.04M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.1% | 1,813 | 1,632 | $1.17M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 6,961 | 6,528 | $923K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 1,198 | 988 | $523K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 6,250 | 5,481 | $427K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 1,639 | 1,413 | $368K |
| 80053 | Comprehensive metabolic panel | 2.2% | 14,721 | 12,755 | $323K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 6,546 | 5,453 | $252K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 3,185 | 2,970 | $246K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 17,507 | 15,091 | $232K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 3,404 | 2,910 | $208K |
195 more codes
| 62323 | 1.4% | 749 | $199K | |
| 71045 | Radiologic examination, chest; single view | 1.3% | 3,380 | $183K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 14,547 | $159K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 3,087 | $158K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 4,601 | $154K |
| 84484 | <1% | 2,857 | $143K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 18,223 | $137K |
| 80047 | <1% | 3,317 | $115K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 235 | $108K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,349 | $103K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 9,608 | $102K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 7,849 | $94K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 17,460 | $89K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,530 | $89K |
| 87641 | <1% | 1,208 | $85K | |
| 97597 | <1% | 1,422 | $85K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 785 | $84K |
| 80050 | General health panel | <1% | 1,182 | $77K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,665 | $76K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,910 | $76K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,603 | $73K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,640 | $73K |
| 83605 | <1% | 2,370 | $72K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 426 | $71K |
| 83690 | <1% | 3,127 | $69K | |
| 81001 | <1% | 5,771 | $66K | |
| 43248 | <1% | 84 | $65K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,560 | $65K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 458 | $63K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,790 | $61K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,037 | $61K |
| 87186 | <1% | 2,450 | $61K | |
| 87428 | <1% | 2,007 | $61K | |
| 73630 | <1% | 720 | $55K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,187 | $54K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,382 | $53K |
| 81025 | <1% | 3,347 | $51K | |
| 62321 | <1% | 151 | $49K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,132 | $49K |
| 87077 | <1% | 2,766 | $48K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,931 | $48K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 80 | $46K |
| 64483 | <1% | 135 | $42K | |
| 51798 | <1% | 625 | $42K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,814 | $41K |
| 80061 | Lipid panel | <1% | 2,964 | $41K |
| 96376 | <1% | 1,064 | $36K | |
| 73610 | <1% | 429 | $35K | |
| 82803 | <1% | 838 | $34K | |
| 71250 | <1% | 147 | $34K | |
| 84145 | <1% | 416 | $34K | |
| 85014 | <1% | 3,554 | $33K | |
| 81003 | <1% | 8,703 | $31K | |
| 83880 | <1% | 645 | $29K | |
| 86140 | <1% | 2,927 | $27K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 346 | $27K |
| 11721 | <1% | 1,917 | $27K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,768 | $26K |
| 87040 | <1% | 762 | $26K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,553 | $25K |
| 85652 | <1% | 2,281 | $24K | |
| 73130 | <1% | 298 | $24K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,266 | $24K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 1,522 | $23K |
| 85610 | <1% | 1,931 | $22K | |
| 11056 | <1% | 745 | $21K | |
| 82077 | <1% | 400 | $21K | |
| 80305 | <1% | 2,496 | $21K | |
| 87070 | <1% | 1,756 | $21K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 118 | $20K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $18K |
| 87205 | <1% | 1,354 | $18K | |
| 85379 | <1% | 271 | $18K | |
| 73562 | <1% | 225 | $17K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,068 | $16K |
| 83735 | <1% | 1,680 | $16K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,067 | $15K |
| 80076 | <1% | 647 | $15K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,250 | $15K |
| 76830 | Ultrasound, transvaginal | <1% | 82 | $14K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,814 | $14K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,428 | $14K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,062 | $13K |
| 74019 | <1% | 226 | $13K | |
| 85027 | <1% | 1,169 | $13K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 125 | $12K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 42 | $12K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 337 | $11K |
| 73030 | <1% | 176 | $11K | |
| 72100 | <1% | 180 | $11K | |
| 80299 | <1% | 104 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,793 | $10K |
| 73110 | <1% | 123 | $10K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 860 | $10K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 845 | $10K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,121 | $9K |
| 82553 | <1% | 232 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,470 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 599 | $8K |
| 82550 | <1% | 514 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,461 | $7K |
| 84439 | <1% | 705 | $7K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $7K |
| 85007 | <1% | 597 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,248 | $7K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 653 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,471 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,115 | $6K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,186 | $6K |
| 83874 | <1% | 128 | $5K | |
| 85730 | <1% | 208 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,794 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 34 | $4K |
| 94729 | <1% | 72 | $4K | |
| 82570 | <1% | 605 | $3K | |
| 36416 | <1% | 1,604 | $3K | |
| 82075 | <1% | 213 | $3K | |
| 82607 | <1% | 201 | $3K | |
| 94060 | <1% | 30 | $3K | |
| 82150 | <1% | 171 | $3K | |
| 86803 | <1% | 217 | $3K | |
| 87081 | <1% | 219 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 145 | $2K |
| 84703 | <1% | 136 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 244 | $2K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 176 | $2K |
| 20610 | <1% | 35 | $2K | |
| 82565 | <1% | 63 | $2K | |
| 84550 | <1% | 237 | $2K | |
| 82043 | <1% | 188 | $2K | |
| 87340 | <1% | 150 | $1K | |
| 80143 | <1% | 15 | $1K | |
| 94726 | <1% | 46 | $1K | |
| 86235 | <1% | 44 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,737 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 41 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 299 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 164 | $1K |
| 83970 | <1% | 54 | $1K | |
| 82805 | <1% | 30 | $1K | |
| 84481 | <1% | 84 | $1K | |
| 83540 | <1% | 145 | $1K | |
| 73502 | <1% | 38 | $1K | |
| 74018 | <1% | 13 | $976.34 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,036 | $935.28 |
| 87807 | <1% | 14 | $933.57 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 230 | $924.23 |
| 84100 | <1% | 191 | $902.22 | |
| 82728 | <1% | 74 | $889.80 | |
| 86038 | <1% | 99 | $841.43 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 458 | $778.45 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 125 | $767.69 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 694 | $700.76 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 979 | $689.84 |
| 86039 | <1% | 53 | $654.42 | |
| 84153 | <1% | 38 | $649.79 | |
| 62369 | <1% | 24 | $624.49 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 80 | $617.02 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 37 | $569.20 |
| 36600 | <1% | 69 | $540.28 | |
| 96127 | <1% | 957 | $532.40 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 106 | $529.98 |
| 90715 | <1% | 13 | $491.86 | |
| 86160 | <1% | 14 | $487.99 | |
| 84156 | <1% | 82 | $479.48 | |
| 86704 | <1% | 54 | $453.29 | |
| 86200 | <1% | 28 | $445.18 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 137 | $428.43 |
| 87210 | <1% | 39 | $399.88 | |
| 86431 | <1% | 49 | $381.65 | |
| 83550 | <1% | 58 | $352.11 | |
| 80069 | <1% | 26 | $341.88 | |
| 80320 | <1% | 82 | $332.65 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 117 | $314.33 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 58 | $309.62 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 48 | $308.12 |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 107 | $204.51 |
| 82375 | <1% | 13 | $191.87 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12 | $174.88 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 38 | $168.81 |
| 82746 | <1% | 12 | $113.77 | |
| 82977 | <1% | 17 | $95.39 | |
| 86225 | <1% | 13 | $80.89 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 22 | $79.80 |
| 82962 | <1% | 56 | $73.69 | |
| 90686 | <1% | 24 | $55.15 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 13 | $49.96 |
| 90688 | <1% | 20 | $22.34 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 31 | $16.89 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 16 | $15.14 |
| A6260 | Wound cleansers, any type, any size | 0% | 46 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 102 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 77 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOWN, ALEX (CFO)
| Provider | Location | Paid |
|---|---|---|
| Tri-State Memorial Hospital | Clarkston, WA | $3.72M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.